GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amarantus Bioscience Holdings Inc (OTCPK:AMBS) » Definitions » Volatility

Amarantus Bioscience Holdings (Amarantus Bioscience Holdings) Volatility : 108.44% (As of May. 28, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Amarantus Bioscience Holdings Volatility?

Volatility is a statistical measure of the dispersion of returns for a given security or market index, it shows how the price swings around its mean. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year. In most cases, the higher the volatility, the riskier the security.

As of today (2024-05-28), Amarantus Bioscience Holdings's Volatility is 108.44%.


Competitive Comparison of Amarantus Bioscience Holdings's Volatility

For the Biotechnology subindustry, Amarantus Bioscience Holdings's Volatility, along with its competitors' market caps and Volatility data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amarantus Bioscience Holdings's Volatility Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Amarantus Bioscience Holdings's Volatility distribution charts can be found below:

* The bar in red indicates where Amarantus Bioscience Holdings's Volatility falls into.



Amarantus Bioscience Holdings  (OTCPK:AMBS) Volatility Calculation

The annualized volatility is calculated as following:

σA=σM * 12
= 1/(n-1) ∑(Ri - R')^2 * 12

Where: σM is the monthly volatility, n is the number of months in the period, Ri is the security's historical monthly returns and R' is the arithmetic mean of monthly returns.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Amarantus Bioscience Holdings  (OTCPK:AMBS) Volatility Explanation

Volatility is a statistical measure of the dispersion of returns for a given security or market index. It’s often measured as standard deviation or variance of historical returns over a certain period. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year.

Volatility reflects the uncertainty or risk of a security’s value. Generally speaking, a higher volatility suggests a higher risk, because it implies a wider fluctuation around average price. This means the price of the security can change dramatically in either direction within a short period. Conversely, a lower volatility means that the security's price is more steady, which suggests a lower risk.

Another measurement of relative volatility is Beta. Beta is a measure of systematic risk of a security or a portfolio in comparison to the market as a whole. Beta is usually compared to 1. A beta of greater than 1 indicates that the security's price will be more volatile than the market.


Amarantus Bioscience Holdings Volatility Related Terms

Thank you for viewing the detailed overview of Amarantus Bioscience Holdings's Volatility provided by GuruFocus.com. Please click on the following links to see related term pages.


Amarantus Bioscience Holdings (Amarantus Bioscience Holdings) Business Description

Traded in Other Exchanges
N/A
Address
45 Wall Street, Suite 920, New York, NY, USA, 10005
Amarantus Bioscience Holdings Inc is a biopharmaceutical company. It is focused on developing therapeutic products for orphan drug designation in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, and diagnostics in neurology. The company's prime therapeutic program, eltoprazine is a small molecule indicated for the treatment of Levodopa-induced dyskinesia. The group's diagnostics division is dedicated to the development and commercialization of neurology diagnostic products. Its diagnostic product, LymPro Test is a blood-based assay to diagnose Alzheimer's disease.
Executives
Flanigan Conn other: Former Director 1601 BLAKE STREET, SUITE 310, DENVER CO 80202
Robert Edward Farrell officer: CFO BIOVEST INTERNATIONAL, INC., 300 S HYDE PARK AVENUE, SUITE 210, TAMPA FL 33606
Joseph Rubinfeld director C/O SUPERGEN INC, 4140 DUBLIN BLVD STE 200, DUBLIN CA 94568